MARKET

CLRB

CLRB

Cellectar
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.538
+0.058
+2.34%
Closed 16:00 01/17 EST
OPEN
2.440
PREV CLOSE
2.480
HIGH
2.555
LOW
2.440
VOLUME
49.31K
TURNOVER
--
52 WEEK HIGH
3.750
52 WEEK LOW
1.040
MARKET CAP
23.82M
P/E (TTM)
-1.0738
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CLRB and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CLRB News

  • Should You Be Concerned About Cellectar Biosciences, Inc.'s (NASDAQ:CLRB) Historical Volatility?
  • Simply Wall St..19h ago
  • Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020
  • GlobeNewswire.01/09 13:00
  • Humana Tax Repeal, And Other News: The Good, Bad, And Ugly Of Healthcare
  • Seeking Alpha - Article.01/07 14:44
  • Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer
  • GlobeNewswire.01/07 13:00

More

Industry

Pharmaceuticals
+0.13%
Pharmaceuticals & Medical Research
+0.07%

Hot Stocks

Name
Price
%Change

About CLRB

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.
More

Webull offers Cellectar Biosciences Inc (CLRB) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.